13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA209-274

    Acronym: 

    Checkmate 274

    ACTRN/NCT /ethics: 

    NCT02632409

    Scientific title: 

    An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

    Summary of trial and patient characteristics

    Cancer Type Other
    Trial Type Treatment
    Phase Phase III Tumour Stream Urothelial carcinoma Bladder cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2016-02-11
    Molecular Target Anticipated End Date 2026-11-27
    Cancer Type Other
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Urothelial carcinoma Bladder cancer
    Cancer Stage All stages
    Anticipated Start Date 2016-02-11
    Anticipated End Date 2026-11-27

    Trial Summary

    A phase III randomised, double-blind, multi-center study of adjuvant nivolumab vs. placebo in subjects with high risk invasive urothelial carcinoma

    Lay Summary

    An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

    Sponsor / Cooperative group

    Bristal-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Lyell McEwin Hospital Andy Phay andy.phay@sa.gov.au 08 8282 0833 Dr Christopher Hocking Recruiting